Market capitalization | $171.14m |
Enterprise Value | $132.16m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.36 |
P/S ratio (TTM) P/S ratio | 5.65 |
P/B ratio (TTM) P/B ratio | 5.57 |
Revenue growth (TTM) Revenue growth | 303.87% |
Revenue (TTM) Revenue | $30.28m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a scPharmaceuticals, Inc. forecast:
6 Analysts have issued a scPharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 30 30 |
304%
304%
|
|
Gross Profit | 21 21 |
333%
333%
|
|
EBITDA | -63 -63 |
29%
29%
|
EBIT (Operating Income) EBIT | -64 -64 |
28%
28%
|
Net Profit | -80 -80 |
59%
59%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Head office | United States |
CEO | John Tucker |
Employees | 136 |
Founded | 2013 |
Website | www.scpharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.